Shire's New Product Portfolio Delivers Strong Quarterly P...(sales ofVYVANSE for 2008 was the lower e...)

Date:10/29/2008

sales of VYVANSE for 2008 was the lower end of a range of $350 to $400 million. We have highlighted a number of variables that would impact the sales growth of VYVANSE during the second half of the year and beyond. We are pleased with the consistent market share gains that VYVANSE has achieved in the third quarter and during the start of the fourth quarter. Based on current sales trends we now believe that 2008 VYVANSE net sales will be in the range of current published analyst estimates of $310m to $330m.

We are encouraged that VYVANSE has now achieved a market share of 10.2% in the week ending October 17th, which represents an annual net sales run rate of over $370m. Based on the current US ADHD market gross sales value of $4bn, each 1% increase in VYVANSE's market share currently represents an additional $36m of annual net sales.

- The costs associated with the launch of FIRAZYR in the EU and continued development of FIRAZYR in the US are now included within our previous guidance ranges. Previous guidance excluded all Jerini AG ("Jerini") related costs.

2009 Financial Outlook

Anticipation of generic competition to ADDERALL XR during 2009 has led to a wide range of external earnings estimates for 2009. To address this, we are providing one time high level confirmation of our expectations for 2009.

Our plans for 2009, based on 2008 year to date actual foreign exchange rates (EUR1:$1.52, GBP1:$1.95) support a Non GAAP diluted earnings per ADS for 2009 in the range of $3.00 to $3.40. This is in line with many market estimates. In recent weeks we have seen significant movements in foreign exchange rates. Each 10c movement in the Euro:$ and GBP:$ exchange rates impacts Shire's Non GAAP diluted earnings per ADS by $0.10 and $0.01 respectively. If rates in 2009 were to average EUR1:$1.35 and GBP1:$1.70, Non GAAP diluted earnings per ADS would be in the range of $2.80 to $3.20.

Shire's management expects that the new product port
'/>"/>

SOURCE Shire Plc Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related biology technology :

1. Beckman Coulter Signs Agreements with Adventist Health; Broad Product Offering Enhances Delivery of Quality Patient Care
2. PEAK Surgical Introduces PlasmaBlade(TM) Product Line Extensions for Use in General Surgery
3. Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States
4. GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology
5. Consumers Looking to Sustainable Food Production to Feed Global Population
6. Contour Products Introduces Groundbreaking Sleep Apnea, Respiratory and Ergonomic Body Comfort Pillows at Medtrade; Self-Explanatory Products Serve Customer Needs, Expand Retailers DME Offerings
7. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
8. Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production
9. Ventria Expands Lactoferrin Production
10. China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million
11. Advanced Analytical Technologies, Inc. Expands Into New Office and Production Space